Fanapt iloperidone Updated Oct 28
Fanapt has no hard binary catalyst in the next 12 months. Watch the Q3 2026 earnings call today (October 28) for the latest Fanapt prescription trends, as well as the December 12, 2026 PDUFA for imsidolimab (a different Vanda asset). The key long-term question is how quickly the next-gen asset BYSANTI (milsaperidone, approved February 2026) cannibalizes or replaces Fanapt revenue as generic iloperidone pressure builds.
- Fanapt prescription growth is accelerating: total prescriptions rose 31% YoY and new-to-brand prescriptions rose 32% YoY in Q2 2026, driven by the newer bipolar I disorder label expansion.
- Fanapt generated $117.3M in net sales in 2025 (up 24% YoY) and represents 54% of Vanda's total revenue, making it the company's largest and fastest-growing commercial product.
- Vanda developed BYSANTI (milsaperidone), an active metabolite of Fanapt approved as a new chemical entity in February 2026 with patent protection extending to the 2040s, providing a follow-on lifecycle strategy.
- Generic iloperidone is already available from at least 3 manufacturers, which limits pricing power and long-term revenue growth potential for Fanapt.
- The FDA approval of BYSANTI (milsaperidone), Fanapt's own active metabolite, introduces a potential cannibalization risk if patients and prescribers switch to the newer chemical entity.
- Vanda's total revenue is under pressure beyond Fanapt: HETLIOZ sales declined 66% YoY in Q2 2026 due to generic competition, and the company is burning cash according to some analysts.